

Supplementary Table S8. Overall survival (OS) and immune cell parameters in high-grade serous ovarian cancer patients

Variable	Group	Median OS (mo)	HR	95% CI	p-value
CD45 ⁺	High	18	1.513	0.7451 to 3.072	.2252
	Low	29			
EpCAM ⁺	High	22	1.331	0.6578 to 2.693	.4078
	Low	29			
CD19 ⁺ CD20 ⁺	High	19	1.257	0.623 to 2.548	.5144
	Low	23			
CD16 ⁺ CD56 ⁺	High	29	0.7620	0.3013 to 1.927	.5419
	Low	19			
CD3 ⁺	High	15	2.826	1.357 to 5.887	.0020
	Low	32			
CD4 ⁺	High	17	2.431	1.183 to 4.996	.0087
	Low	32			
CD4 ⁺ CD25 ⁺	HIGH	23	0.9160	0.4521 to 1.856	.8021
	Low	22			
CD25 ^{high} CD127 ^{low} Tregs	High	23	0.8081	0.3874 to 1.686	.5382
	Low	20			
CD8 ⁺	High	23	1.092	0.5390 to 2.213	.8011
	Low	29			
CD8 ⁺ PD-1 ⁺	High	23	0.9799	0.4843 to 1.983	.9532
	Low	23			
CD4 ⁺ PD-1 ⁺	High	29	0.6292	0.3092 to 1.280	.1761
	Low	23			
CD68 ⁺	High	23	1.076	0.5187 to 2.232	.8387
	Low	23			
CD163 ⁺	High	29	0.8114	0.3857 to 1.707	.5565
	Low	19			
CD68PD-L1	High	29	0.5362	0.2462 to 1.168	.1006
	Low	16			
CD163 ⁺ PD-L1 ⁺	High	29	0.6123	0.2531 to 1.481	.2333
	Low	23			
EpCAM ⁺ PD-L1 ⁺	High	22	1.187	0.5517 to 2.556	.6600
	Low	32			

Immune-cell variables were dichotomized into high- and low-expression groups using the median value of the corresponding marker in the survival-analysis cohort. HRs are reported for the high-expression group relative to the low-expression group.

HR, hazard ratio; CI, confidence interval.